Characterization of Transcription Factor Networks Involved in Umbilical Cord Blood CD34+ Stem Cells-Derived Erythropoiesis

Biaoru Li1, Lianghao Ding2, Chirnrang Yang2, Baolin Kang1, Li Liu3, Michael D. Story2, Betty S. Pace1*

1 Department of Pediatrics, Hematology/Oncology Division, Georgia Regents University, Augusta, Georgia, United States of America, 2 Department of Radiation Oncology and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America, 3 Department of Molecular and Cell Biology, University of Texas at Dallas, Richardson, Texas, United States of America

Abstract

Fetal stem cells isolated from umbilical cord blood (UCB) possess a great capacity for proliferation and differentiation and serve as a valuable model system to study gene regulation. Expanded knowledge of the molecular control of hemoglobin synthesis will provide a basis for rational design of therapies for β-hemoglobinopathies. Transcriptome data are available for erythroid progenitors derived from adult stem cells, however studies to define molecular mechanisms controlling globin gene regulation during fetal erythropoiesis are limited. Here, we utilize UCB-CD34+ stem cells induced to undergo erythroid differentiation to characterize the transcriptome and transcription factor networks (TFNs) associated with the γ/β-globin switch during fetal erythropoiesis. UCB-CD34+ stem cells grown in the one-phase liquid culture system displayed a higher proliferative capacity than adult CD34+ stem cells. The γ/β-globin switch was observed after day 42 during fetal erythropoiesis in contrast to adult progenitors where the switch occurred around day 21. To gain insights into transcription factors involved in globin gene regulation, microarray analysis was performed on RNA isolated from UCB-CD34+ cell-derived erythroid progenitors harvested on day 21, 42, 49 and 56 using the HumanHT-12 Expression BeadChip. After data normalization, Gene Set Enrichment Analysis identified transcription factors (TFs) with significant changes in expression during the γ/β-globin switch. Forty-five TFs were silenced by day 56 (Profile-1) and 30 TFs were activated by day 56 (Profile-2). Both GSEA datasets were analyzed using the MIMI Cytoscape platform, which discovered TFNs centered on KLF4 and GATA2 for Profile-1 and KLF1 and GATA1 for Profile-2 genes. Subsequent shRNA studies in KU812 leukemia cells and human erythroid progenitors generated from UCB-CD34+ cells supported a negative role of MAFB in γ-globin regulation. The characteristics of erythroblasts derived from UCB-CD34+ stem cells including prolonged γ-globin expression combined with unique TFNs support novel mechanisms controlling the γ/β-globin switch during UCB-derived erythropoiesis.

Introduction

UCB-CD34+ stem cells (UCB-SC) represent a powerful paradigm for exploring many aspects of cell biology and hold considerable promise as a therapeutic option for hematopoietic stem cell transplantation and ex vivo gene therapy. A large body of evidence suggests that UCB-SC have unique biological characteristics including growth kinetics, morphology, phenotype, differentiation potential and engraftment capacity when compared to adult bone marrow-derived CD34+ stem cells [1–2]. These features provide the impetus for developing UCB-SC for pre- and post-natal therapy for malignant [3] and inherited β-hemoglobinopathies such as thalassemia major [4] and sickle cell disease [5]. However, the molecular mechanisms that control UCB-SC derived erythropoiesis including globin gene regulation remain unclear. Therefore, we utilized UCB-SC induced to undergo erythroid maturation as a model for characterizing the fetal transcriptome to gain insights into globin gene regulation. The major protein produced during erythropoiesis is hemoglobin produced from five functional genes (α, Αγ, Βγ, δ, and β-globin) located in the β-locus on chromosome 11, expressed in a stage-specific manner during development [6]. The normal switch from γ- to β-globin (γ/β-globin) gene expression occurs after birth by one year of life.

To date, gene profiling during human erythroid differentiation using various liquid culture systems have been published, contributing insights into differentially expressed genes and the molecular control of lineage commitment [7–8]. For example, Merryleweather-Clarke et al. used peripheral blood mononuclear cells combined with fluorescence-activated cell sorting to generate expression data from erythroid progenitors generated in culture [9]. Our laboratory recently characterized the transcriptome...
associated with the γ/β-globin gene switch in erythroid progenitors derived from adult bone marrow CD34+ stem cells [10]. Although an increasing number of studies have addressed the transcriptome of adult erythropoiesis, limited data are available for erythropoiesis in fetal progenitors and the TFNs involved in the γ/β-globin switch.

The impetus for defining TFs involved in hemoglobin switching is to develop strategies for fetal hemoglobin (HbF; α2γ2) induction to treat sickle cell anemia caused by an A to T mutation in the γ-globin chain. This mutation leads to hemoglobin S production which is subjected to non-covalent polymerization under low oxygen conditions. Many studies describing naturally occurring mutations producing hereditary persistence of HbF lead to success in inducing HbF in the majority of sickle cell patients [12,13], defining global mechanisms of γ-globin regulation have the potential to provide alternative approaches for HbF induction in non-responsive individuals.

The majority of studies to identify regulators of γ-globin transcription have utilized cell lines [14], adult stem cells [15] or animal models [16]. Recent human genetic studies revealed an association of mutations in the BCL11A gene and inherited HbF levels [17] which were demonstrated to be involved in the γ/β-globin switch in transgenic mice [18]. Subsequent studies demonstrated that KLF1, an erythroid-specific protein which directly activates β-globin [19] also regulates BCL11A [20,21]. The latter is a repressor that binds to sequences in the locus control region (LCR) and downstream of Aγ-globin in adult erythroid progenitors to silence γ-globin expression through protein-protein interactions with Sox6 [22]. In this study, we used UCB-SC as a model to characterize the transcriptome and TFNs involved in globin gene regulation during fetal erythropoiesis.

Gene Set Enrichment Analysis identified 45 TFs silenced by day 56 (Profile-1) and 30 TFs activated by day 56 (Profile-2) in culture. Subsequent MIMI Cytoscape platform analysis discovered novel TFNs centered on KLF4 and GATA2 (Profile-1) and KLF1 and GATA1 for Profile-2 genes. Subsequent shRNA studies in human erythroid progenitors generated from UCB-CD34+ cells supported a negative role of MAFB in γ-globin regulation.

Materials and Methods

One-phase Erythroid Culture

UCB-derived CD34+ stem cells (STEMCELL Technologies, Vancouver, Canada) were grown in the one-phase liquid culture system as previously published [23]. Briefly, cells were cultured in αMEM containing 30% fetal bovine serum (Atlanta Biologicals, Atlanta, GA), stem cell factor (50 ng/mL), interleukin-3 (10 ng/mL) and erythropoietin (4IU/mL) starting on day 0. Three million cells were harvested every 7 days for the different studies. For biomarkers analyses single layer cell smears were made by cytopsin preparations and fixed in 4% paraformaldehyde. Cells were stained with FITC conjugated anti-CD34 and anti-CD235a antibodies, and PE conjugated anti-CD71 antibody (eBioscience, San Diego, CA). The number of biomarker positive cells was counted using a florescent microscope (Zeiss, Avix Vision 4.8); at least 500 cells were counted per slide in triplicate for each time point analyzed.

Reverse transcription-quantitative PCR (RT-qPCR) analysis

The mRNA levels of γ-globin, β-globin, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were measured as previously published [24]. Total RNA was extracted from 3×10⁶ cells and the different cDNAs were prepared using the Improm-II RT system (Promega, Madison, WI). The γ-globin, β-globin, and GAPDH mRNA levels were quantified by Sybergreen qPCR (iCycler 95 iQ, Bio-Rad).

Illumina BeadChip Microarray Analysis

Total RNA isolated on day 21, 42, 49 and 56 was used for microarray analysis on the Illumina HumanHT-12 V4 Expression BeadChip platform (Illumina, Inc., San Diego, CA) as previously published [25]. Quality checked cRNA was hybridized to the Illumina BeadChip using streptavidin-Cy-3 for detection and chips were scanned on an Illumina Beadstation. The raw data are available through the National Center for Biotechnology Information Gene Expression Omnibus database, accession number GSE49438.

Microarray Confirmation

RT-qPCR was used to confirm microarray data as previously published [10]. Gene specific primers were designed using Primer3 software. To validate the microarray data we chose a subset of Profile-1 and Profile-2 genes. The correlation coefficient (R²) and confidence intervals were generated using the Student’s t-test, p<0.05.

Principal Component Analysis (PCA)

The raw data obtained from the Illumina Beadstation were summarized as probe level signal intensities using Illumina BeadStudio v2.1.3, then background subtraction and quantile normalization were completed using the MBCB (Model-Based Background Correction for BeadArrays) algorithm [26]. After data normalization, we defined gene expression patterns during fetal erythropoiesis and performed time-course analysis with PCA (NIA Array Analysis Tool) as previously published [10,27]. The data were analyzed at the >1.5-fold change levels in a time-course manner on days 21, 42, 49 and 56 to define two major gene expression profiles.

Gene Set Enrichment Analysis (GSEA)

We performed GSEA [28] to enrich for transcription factors with >1.5-fold changes in expression between day 21 (high γ-globin) and day 56 (high β-globin) by PCA. GSEA is a computational method that determines whether an a priori defined set of genes shows statistically significant, concordant differences between two biological states. The method derives its power by focusing on gene sets that share common biological function, chromosomal location, or regulation. For our GSEA analysis we interrogated three gene sets including TF activity, TF complex and DNA binding. For computing the statistical significance of a biological category, 100 permutations were performed with phenotype comparison ranking established by Signal2Noise, a metric parameter for enrichment and the Meandiv test for normalization models. Two measures were generated by GSEA including the enrichment score (ES) and the gene ranked list metric. The ES reflects the degree to which a gene set is overrepresented at the top or bottom of a ranked list of genes. Our ranked list metric measures a gene’s correlation with the Profile-1 or Profile-2 phenotypes. After GSEA the TFs identified were analyzed by hierarchical clustering using the BRB ArrayTool to confirm expression patterns during erythropoiesis.

TESS and TFSEARCH analysis

To search for putative TF binding motifs in the β-locus on chromosome 11, TESS and TFSEARCH software tools were used.
used. The Genome Browser (http://genome.ucsc.edu/) was employed to confirm motif coordinates in the Human Genome, version Hg19.

Cytoscape Michigan Molecular Interaction (MiMI) Analysis
Cytoscape is an open source software platform for visualizing complex networks and integrating them with attribute data. MiMI is a plugin for Cytoscape to study molecular interactions from the MiMI database and to display the interaction network(s) in Cytoscape [29]. This approach was used to display the TFNs established using genes identified by GSEA.

ENCODE Analysis
Data tracks from the ENCODE project were downloaded and analyzed using the UCSC Genome Browser. Our analysis covered the genomic region from 5,237,658 to 5,318,750 (the β-locus on chromosome 11). The gene transcription (RNA-seq), histone modification, and ChIP-seq (in vivo TF binding) tracks were generated from data produced by the ENCODE consortium.

Lentivirus-mediated shRNA Gene silencing
GIPZ lentiviral shRNA particles were purchased from Thermo Fisher Scientific Inc. (Waltham, MA). KU812 cells (90,000) were transduced with 20 MOI of lentivirus particles in serum-free media for 4 hr and then 10% fetal bovine serum was added. Puromycin (0.6 µg/ml) was added on day 2 and selection performed for 5 days. The cells were harvested for RT-qPCR using gene-specific primers purchased from SuperArray (Qiagen, Valencia, CA); relative gene expression levels were calculated using the 2^ΔΔCt method. After lentiviral transduction fluorescent activated cell sorting (FACS) was performed at 48 hr to determine transfection efficiency. The percentage of green fluorescence protein (GFP) positive cells was used to normalize the qPCR data.

Transduction of erythroid progenitors
Erythroid cells were generated from UCB-SC in culture as described in the One-phase Erythroid Culture section. On day 49 erythroid progenitors (90,000) were transduced with 20 MOI of the different lentivirus particles in serum-free media for 4 hr then cells were grown in complete medium for the duration of culture. Puromycin (0.6 µg/ml) was added at day 51 and cells were harvested at day 56 for GFP expression by FACS to determine transfection efficiency and RT-qPCR analysis. The γ-globin and β-globin gene expression levels were normalized by %GFP positive cells and expressed as a ratio of γ/γ+β and β/γ+β.

Fluorescent Activated Cell Sorting (FACS) analysis
After virus transductions 300,000 KU812 cells or erythroid progenitors were washed twice with phosphate buffered saline then fixed in 4% paraformaldehyde and permeated with ice-cold acetone/methanol (4:1). Cells were incubated with anti-γ-globin-FITC antibody (Santa Cruz Biotechnology, Santa Cruz, CA) in PBT (PBS/0.1%BSA/0.1% triton X100) solution. The labeled cells were analyzed by FACS on a Bectin Dickerson LSR-II flow cytometer (BD Bioscience). All experimental were performed in triplicate of three to five independent viral transductions.

Results and Discussion

Normal erythropoiesis is observed in UCB-stem cells
To study global gene expression patterns in UCB-SC, we used the one-phase liquid culture system as previously published [23]. Cell growth curves, viability, morphology and differentiation biomarkers measured during UCB-SC erythropoiesis displayed a high growth potential by day 56 in cultures (Figure 1A). We observed 72% orthochromatophilic erythroblasts by the end of culture period (Figure 1B and 1C) with greater than 93% viability at the time of cell harvest (Figure S1 in File S1). Loss of CD34 expression and increased CD71 and CD235a expression confirmed erythroid commitment (Figure 1D) and maturation of erythroid progenitors in our system. We did not observe significant enucleation of progenitors by day 56 therefore our system is not optimal for investigating the transcriptome of reticulocytes and mature red blood cells.

The γ/β-globin switch is recapitulated in UCB-stem cells
To substantiate this system as a model to study TFNs involved in hemoglobin switching, γ-globin and β-globin mRNA levels were quantified by RT-qPCR. Before day 14 the γ- and β-globin genes were expressed at low levels (data not shown) however by day 21 when erythroid progenitors reached a significant level (Figure 1C), γ-globin expression predominated with the γ/β-globin switch occurring after day 42 (Figure 2A). This pattern of globin expression in different than adult stem cell erythropoiesis where γ-globin predominates by day 7 and the γ/β-globin switch occurred around day 21 (Figure S2 in File S1) [10]. These data demonstrate the γ-globin gene is active for a longer period in fetal erythroid progenitors suggesting different mechanisms of globin gene regulation might occur in these two cell models.

We observed changes in globin gene expression as progressively more mature erythroblasts appear in culture. However in our system, erythroblasts may be sequentially generated by progenitors generated at different points in culture since CD34+ cells are detected up to day 49 (Figure 1D). The latter possibility is supported by the fact that mature red blood cells survive in culture about 7 days but the lack of enucleation in the one-phase culture supports longer survival for erythroblasts. Comparison of the globin genes expressed in cells generated from erythroblasts and CD34+ cells purified at different time points is required to clarify this point.

Fetal hemoglobin is a heterogeneous mixture of γ-globin polypeptide chains containing either glycine (Gγ) or alanine (Aγ) at residue 136; Aγ-chains increase from a 3:1 to 1:1 Gγ:Aγ ratio during the first year of life. To further substantiate our system we determined the Gγ- and Aγ-globin expression patterns using gene-specific primers. As shown in Figure 2B, the Gγ:Aγ-globin ratio changed from 2.3:1 at day 7 to 1:1 by day 42 recapitulating expression patterns observed in the first year of life.

Finally, to investigate γ-globin activation in our system erythroid progenitors were treated with hemin, a known HbF inducer, at two time points corresponding to high γ-globin (day 42) and low γ-globin (day 36) expression. As shown in Figure 2C hemin (50 μM) activated γ-globin 2.2-fold after 72 hr of treatment, which was lost at the later time point. These data support the ability of hemin to further enhance a transcriptionally active γ-globin gene compared to when the gene is silenced at the end of culture. Data supporting the γ/β-globin switch, change in the Gγ:Aγ ratios, and HbF induction by hemin support the capacity of our culture system to define global TFNs associated with hemoglobin switching during fetal erythropoiesis. This type of analysis has not been completed to date. Nevertheless, our system has limitations due to the isolation of RNA from mixtures of erythroblast at the different time points. To address this limitation we performed siRNA functional studies to determine if the TFs identified by bioinformatics analysis have an effect on γ-globin transcription.
Gene expression profiling during fetal erythropoiesis

To map gene expression profiles we collected samples at day 21, 42, 49, and 56 based on the timing of the γ/β-globin switch (Figure 2A). Using MBCB software, the raw data were normalized for variations in gene expression between replicates (Figure S3 in File S1 and Table S1), and the quality of data at each time point was further studied by regression analysis. The normalized triplicates at day 21 showed $R^2 = 0.99$, day 42 $R^2 = 0.96$, day 49 $R^2 = 0.98$, and at day 56 $R^2 = 0.95$ demonstrating good correlation of data reproducibility.

PCA defines Profile-1 and Profile-2 gene expression patterns

We subsequently generated major gene expression patterns using PCA to build a model to define the TFs involved in hemoglobin switching. We hypothesized that Profile-1 TFs with an expression pattern similar to γ-globin (genes silenced from day 21 to day 56) might be activators of γ-globin, or conversely repressors of β-globin. Similarly, Profile-2 genes (activated from day 21 to day 56) might be β-globin activators or repressors of γ-globin. Alternatively, TFs with either expression profile may not play a role in globin gene regulation but rather be involved in normal erythroid maturation. The two gene profile subsets were defined using PCA (Figure 3A) and the normalized data were mined by statistical analysis using an F-distribution with ANOVA = 0.01 and a false discovery rate (FDR) = 0.05 (Table S2). We identified 2,568 Profile-1 and 2,458 Profile-2 genes with >1.5-fold change in expression during fetal erythropoiesis. RT-qPCR was completed for a subgroup of TFs known to be involved in globin gene regulation. We observed GATA2 and BCL11A silencing over 56 days (Figure 3B). The findings for BCL11A are opposite of that observed for adult stem cells [30] supporting difference in gene regulation in fetal progenitors. By contrast, gene activation occurred over the culture period for the Profile-2 genes KLF1, GATA-1 and MXI (Figure 3C). We next confirmed the microarray data with RT-qPCR analysis of 25 Profile-1 and Profile-2 genes combined with regression analysis (Table S3). Our results showed good correlation between the microarray and RT-qPCR datasets with $R^2$ ranging from 0.72 to 0.79. However, confirmation of Profile-2 genes was better than Profile-1 genes which may reflect prolonged culture period for the latter, a finding reported by other laboratories [31].

GSEA and TESS/TFSEARCH analysis identify TFs with altered expression during the γ/β-globin switch and predicted binding in the β-locus

To define TFs involved in the γ/β-globin switch we performed GSEA, which determines whether an a priori defined set of genes show concordant differences between day 21 and day 56 of culture. The ES (enrichment score) reflects the degree to which three TFs gene sets are overrepresented at the top or bottom of a ranked list of genes. A positive or negative ES indicates gene
enrichment at the top or bottom of the ranked list respectively. We input 2568 Profile-1 and 2458 Profile-2 genes and generated a rank ordered list related to the signal to noise ratio; 3786 genes with 1.5-fold change between day 21 and day 56 were ranked. Shown in Table 1 and Table 2 respectively are 40 positively correlated Class A (Profile-1) and 30 negatively correlated Class B (Profile-2) TFs based on ES generated by GSEA (Figure 4A) supporting possible function in erythropoiesis.

Of the Profile-1 genes, we identified GATA2 and KLF4 which are known to be positive regulators of $\alpha$-globin supporting the changes in $\gamma$-globin and $\beta$-globin mRNA levels after normalization by the internal control GAPDH. B) RT-qPCR was performed with $\gamma$- and $\alpha$-globin specific primers to determine the $G_\gamma/A_\gamma$ mRNA ratio during erythropoiesis. A representative gel is shown. $\gamma$-globin expression was normalized to one (black bars) and the relative changes in $A_\alpha$-globin mRNA are shown in the gray bars. C) Progenitors were induced on day 42 or day 56 with 50 $\mu$M hein (HE) for 72 hr and then RT-qPCR was completed to measure $\gamma$-globin and $\beta$-globin mRNA levels.

doi:10.1371/journal.pone.0107133.g002

Figure 2. The $\gamma/\beta$-globin switch is recapitulated in UCB-stem cells. A) RT-qPCR analysis was performed at the days shown to determine changes in $\gamma$-globin and $\beta$-globin mRNA levels after normalization by the internal control GAPDH. B) RT-qPCR was performed with $G_\gamma$- and $A_\gamma$-globin specific primers to determine the $G_\gamma/A_\gamma$ mRNA ratio during erythropoiesis. A representative gel is shown. $G_\gamma$-globin expression was normalized to one (black bars) and the relative changes in $A_\alpha$-globin mRNA are shown in the gray bars. C) Progenitors were induced on day 42 or day 56 with 50 $\mu$M hemin (HE) for 72 hr and then RT-qPCR was completed to measure $\gamma$-globin and $\beta$-globin mRNA levels.

doi:10.1371/journal.pone.0107133.g003

Figure 3. PCA defines major gene profiles during erythropoiesis. A) PCA was performed for gene subsets with >1.5-fold change in expression from day 21 to day 56. The results are shown for the two major gene profiles generated by PCA. The gray line represents the mean value of time course changes in gene expression. B) Microarray data for two known $\gamma$-globin regulators were confirmed by RT-qPCR. C) Microarray data for three Profile-2 genes were confirmed by RT-qPCR.

doi:10.1371/journal.pone.0107133.g003
predictive model and published data from our laboratory [32]. By contrast, Profile-2 TFs such as GATA1 and KLF1 known to be involved in β-globin activation and bind in the LCR [33,34] were identified. Hierarchical clustering was used to visualize the genes identified by GSEA that are silenced and activated during fetal erythropoiesis (Figure 4B).

To provide evidence for a role of the novel TFs identified by GSEA in globin gene regulation, we performed in silico TESS and TFSEARCH analysis to locate predicted binding motifs in the β-locus (Figure S4 in File S1). Using the reference sequence file NG_000007.3 we investigated the LCR consisting of four erythroid-specific DNaseI hypersensitive sites 1 (HS1) to HS4. The LCR is known to bind TFs to mediate an enhancer function.

### Table 1. UCB-stem cell Class A (Profile-1) transcription factors.

| Gene No. | GENE SYMBOL | ENRICHMENT SCORE (ES) | GENE RANK |
|----------|-------------|-----------------------|-----------|
| 1        | WRN         | 0.13921548            | 1273      |
| 2        | RAD51L3     | 0.13392287            | 1131      |
| 3        | HMGB1       | 0.12708704            | 1455      |
| 4        | RAD51C      | 0.12248576            | 1420      |
| 5        | ZHX1        | 0.12059385            | 1453      |
| 6        | MCM2        | 0.11607464            | 760       |
| 7        | ORC1L       | 0.10977035            | 660       |
| 8        | HMGB3       | 0.10697572            | 833       |
| 9        | ORC5L       | 0.0941495             | 956       |
| 10       | WDH1        | 0.093303196           | 996       |
| 11       | ERCC1       | 0.09263573            | 638       |
| 12       | SP1         | 0.0846437             | 1220      |
| 13       | FANCG       | 0.084250145           | 626       |
| 14       | TCF3        | 0.07799235            | 1354      |
| 15       | AEBP1       | 0.076171584           | 1191      |
| 16       | ATF5        | 0.076171584           | 1291      |
| 17       | RBL1        | 0.074729405           | 618       |
| 18       | UHRF1       | 0.070319876           | 1329      |
| 19       | MYCN        | 0.06354961            | 616       |
| 20       | CCNB4L      | 0.061169855           | 1185      |
| 21       | TFA4        | 0.059797958           | 1128      |
| 22       | RAD51       | 0.05145543            | 574       |
| 23       | ABI2        | 0.041926224           | 565       |
| 24       | TP53        | 0.040889304           | 1068      |
| 25       | KLF4        | 0.040889304           | 1068      |
| 26       | MXD3        | 0.03288997            | 554       |
| 27       | SCML1       | 0.030790053           | 1039      |
| 28       | GATA2       | 0.026186744           | 197       |
| 29       | FAF1        | 0.021628574           | 551       |
| 30       | ALKBH2      | 0.021547657           | 320       |
| 31       | SREBF1      | 0.018373493           | 1018      |
| 32       | KIF2C       | 0.016045136           | 527       |
| 33       | FOXD1       | 0.015144873           | 753       |
| 34       | EXO1        | 0.013996358           | 184       |
| 35       | ESR2        | 0.013549825           | 271       |
| 36       | TCF7L2      | 0.012766987           | 448       |
| 37       | SCMH1       | 0.008562001           | 701       |
| 38       | ZMYM3       | 0.006172042           | 518       |
| 39       | ZNF367      | 0.003327756           | 642       |
| 40       | ZNF133      | 0.001190173           | 1014      |

1 ES, enrichment score of TFs identified by GSEA using three TF gene sets (TF activity, TF complex and DNA binding). A positive ES indicates the gene expression correlated with a Profile-1 pattern (decreased expression from day 21 to day 56).

2 Gene Rank, gene rank list generated by GSEA using 3786 TFs with >1.5-fold changes in expression from day 21 to day 56 in culture.

doi:10.1371/journal.pone.0107133.t001
required for developmentally regulated globin gene expression [6]. In the LCR, we identified 15 TF binding motifs for the known globin regulator GATA1 and 5 motifs for NFE2 among others (Table 3 and Table S4); the novel TFs HES5 and HSF1 were also predicted to bind the LCR. A similar analysis for the HBG genes demonstrated binding motifs for Profile-1 genes such as GATA2 and novel factors TCFL7L2 and MXD3 not previously implicated in globin gene regulation (Table S5). Lastly, analysis for the HBB region identified binding motifs for 19 TFs such as the known regulator KLF1 and novel TF MAFB activated by day 56 (Table 3, Table S6). These data may provide insights into the role of novel DNA binding proteins in the ε/β-globin switch during fetal erythropoiesis.

Identification of TFNs involved in erythroid maturation

The next study was conducted to discover fetal erythroid TFNs using the genes defined by GSEA and predicted to bind the β-locus. Network analysis is a recently developed approach to study global gene regulatory pathways to define mechanisms of hemoglobin switching. The MiMI plugin for Cytoscape is a tool which integrates data from multiple well-known protein interaction databases including KEGG and Reactome into a network analysis as shown in Figure 4C (Figure S5 in File S1). We identified TFNs centered on GATA2 and KLF4 for Profile-1 genes and members of this network such as CREBBP and KLF6 regulated by KLF4. These data are consistent with a positive role of KLF4 in ε-globin regulation as previously published from our group [35]. Interestingly CREBBP is predicted to activate GATA2 and HDAC3. Perrine and colleagues demonstrated that knockdown of HDAC3 induces HbF expression due to displacement of this protein from the ε-globin promoter by short chain fatty acid derivatives [36]. How these TFNs controls globin gene regulation required additional studies.

The Cytoscape analysis, demonstrated that KLF1 and GATA1 serve as TFN hubs during late fetal erythropoiesis (Figure 4D and Figure S6 in File S1) consistent with their known role in

Table 2. UCB-stem cell Class B (Profile-2) transcription factors.

| Gene No. | GENE SYMBOL | ENRICHMENT SCORE1 | GENE RANK2 |
|-----------|-------------|-------------------|------------|
| 1         | SON         | -0.05842792       | 2994       |
| 2         | TSC22D3     | -0.058295283      | 2927       |
| 3         | NFX1        | -0.054407794      | 2935       |
| 4         | DMC1        | -0.053078525      | 2844       |
| 5         | ATF3        | -0.051295283      | 2927       |
| 6         | TRIM22      | -0.04250992       | 3495       |
| 7         | SOX6        | -0.04150992       | 3495       |
| 8         | NFkB2       | -0.038754087      | 2935       |
| 9         | BATF        | -0.03710674       | 3189       |
| 10        | GATA1       | -0.03329886       | 3749       |
| 11        | KLF1        | -0.032754087      | 2935       |
| 12        | FOXC1       | -0.030511508      | 3262       |
| 13        | SP140       | -0.03033415       | 3212       |
| 14        | STAT1       | -0.02901836       | 3336       |
| 15        | MAFB        | -0.02863797       | 3306       |
| 16        | GLI2        | -0.02699749       | 3520       |
| 17        | BCL6        | -0.02135538       | 2685       |
| 18        | ZNF256      | -0.0191952        | 2182       |
| 19        | SYCP1       | -0.017439079      | 3545       |
| 20        | CDT1        | -0.017186195      | 2181       |
| 21        | E2F1        | -0.013077641      | 2999       |
| 22        | M010        | -0.012244189      | 3349       |
| 23        | IKZF4       | -0.008271581      | 2442       |
| 24        | HMGAI       | -0.007992041      | 2911       |
| 25        | CREB1       | -0.006540393      | 2653       |
| 26        | JUN         | -0.005443786      | 3064       |
| 27        | OLIG2       | -0.003412304      | 3554       |
| 28        | SIAH2       | -0.002095886      | 3614       |
| 29        | HSF1        | -0.001728075      | 2562       |
| 30        | ZHX2        | -0.00001730       | 2292       |

1ES, enrichment score of TFs identified by GSEA using three TF gene sets (TF activity, TF complex and DNA binding). A negative ES indicates genes with a negative correlation to Profile-1 (i.e. Profile-2 gene with increased expression from day 21 to day 56).

2Gene Rank, gene rank list generated by GSEA using 3786 TFs with 1.5-fold changes in expression from day 21 to day 56 in culture.
doi:10.1371/journal.pone.0107133.t002
hemoglobin switching. Downstream of KLF1, novel proteins such as CSNK2A1 which activates CREBBP but negatively regulates FLII were identified. Positive regulation of CSNK2A1 by KLF1 and the ability of CSNK2A1 to activate CREBBP by phosphorylation have been reported [31]. A replication study in β-thalassemia subjects show a correlation of single nucleotide polymorphisms in the CSNK2A1 gene correlate with fetal hemoglobin levels in this group [37].

Different TFNs are involved in UCB versus adult erythropoiesis

To determine if unique mechanisms of globin gene regulation occur during fetal erythropoiesis, we compared TFNs defined using data generated from UCB versus adult bone marrow CD34+ cells [10] where the γ/β-globin switch occurred after day 42 and day 21 respectively (Figure 2A and Figure S2 in File S1). PCA using day 7 and day 28 data generated with adult erythroid progenitors produced 2649 Profile-1 and 2868 Profile-2 genes. Subsequent GSEA identified 14 Profile-1 (Class A) and 18 Profile-2 (Class B) TFs differentially expressed during adult erythropoiesis (Figure 5A; Table S7); hierarchical clustering demonstrated the genes silenced and activated during the culture period (Figure 5B). Subsequent Cytoscape analysis defined TFNs centered on RUNX3 and KLF12 (Profile-1) before the γ/β-globin switch in adult progenitors (Figure 5C). KLF12 binds the CACCC boxes to regulate globin expression [38]. By contrast, RUNX3 interacts with Scl/Tal1 to control early stem cell development promoting commitment to the erythroid lineage and γ-globin activation [39]. Interestingly, the major Profile-2 TFNs generated for adult and fetal progenitors involve KLF1 and GATA1 (Figure 5D) however the downstream targets were less well defined in adult cells. These data support unique mechanisms of γ-globin regulation during erythropoiesis.
Table 3. TESS/TFSEARCH predicted binding motifs across the β-globin locus.

| Profile | GENE     | Microarray Data1 | Binding Motif2  | Log-likelihood scores3 | LCR4 | γ-globin4 | β-globin4 |
|---------|----------|------------------|-----------------|-----------------------|------|----------|----------|
|         |          | D-21  | D-42  | D-49  | D-56  | TGCAC  | 12      | 8        | 12       | 9       |
| 1       | SP1      | 1.00  | 0.95  | 0.48  | 0.62  | TGCAC  | 12      | 8        | 12       | 9       |
| 1       | KLF4     | 1.00  | 0.97  | 1.01  | 0.78  | CYYYYYTYNTTY  | 14      | 1        | 1        | 1       |
| 1       | GATA2    | 1.00  | 0.95  | 0.57  | 0.32  | AGATAA | 12      | 2        | 2        | 2       |
| 1       | CUX1     | 1.00  | 0.73  | 0.59  | 0.61  | ATGGG  | 10      | 2        | 2        | 2       |
| 1       | KLF11    | 1.00  | 0.95  | 0.57  | 0.32  | TGGGATAT | 12      | 1        | 1        | -       |
| 1       | HESS     | 1.00  | 0.95  | 0.57  | 0.32  | CACCTG  | 12      | 1        | 1        | -       |
| 1       | FAF1     | 1.00  | 0.61  | 0.53  | 0.54  | GGYYAAATTA | 16      | -        | 1        | -       |
| 1       | TCF7L2   | 1.00  | 0.45  | 0.86  | 0.8   | CTTTGTAT | 14      | -        | 1        | -       |
| 1       | FHL2     | 1.00  | 0.84  | 0.72  | 0.45  | AATGGGA | 12      | -        | 1        | -       |
| 1       | MXD3     | 1.00  | 0.82  | 0.83  | 0.39  | CATCTGCC | 12      | -        | 1        | -       |
| 1       | RBL1     | 1.00  | 0.40  | 0.46  | 0.37  | GCAG    | 8       | -        | 1        | -       |
| 2       | GATA1    | 1.00  | 0.81  | 1.32  | 1.4   | RGAGATTA | 16      | 15       | 21       | 10      |
| 2       | ATF3     | 1.00  | 1.69  | 1.85  | 1.43  | TGACGT  | 12      | 1        | 2        | 2       |
| 2       | NFKB2    | 1.00  | 1.54  | 3.31  | 1.65  | GGTAGTTCCC | 20      | 1        | -        | 1       |
| 2       | BATF     | 1.00  | 1.44  | 1.65  | 1.53  | CTCTGTGATGTACATGTTT | 17      | -        | -        | 1       |
| 2       | KLF1     | 1.00  | 1.11  | 1.7   | 1.9   | CCACACCT | 12      | -        | -        | 1       |
| 2       | OLIG1    | 1.00  | 2.95  | 3.47  | 3.22  | TCGATATGG | 12      | -        | -        | 1       |
| 2       | MAFB     | 1.00  | 3.18  | 3.34  | 9.1   | GCGGAAGT | 10      | -        | -        | 1       |
| 2       | OLIG2    | 1.00  | 20.81 | 22.44 | 24.91 | TGCTCT  | 10      | -        | -        | 1       |
| 2       | MXI1     | 1.00  | 3.91  | 5.65  | 4.99  | CACCTG  | 12      | -        | -        | 9       |
| 2       | CREB1    | 1.00  | 1.17  | 0.88  | 2.18  | TGACGC  | 10      | 5        | 2        | 6       |
| 2       | NF-E2    | 1.00  | 1.26  | 1.68  | 1.36  | TATA/GGCCAG | 8       | 1        | 1        | 1       |
| 2       | CREB2    | 1.00  | 1.32  | 1.50  | 1.24  | TTACGTAA | 15      | 1        | 1        | 1       |
| 2       | P300     | 1.00  | 1.58  | 2.37  | 1.55  | GGGAGTG | 14      | 2        | 1        | 1       |
| 2       | Jun      | 1.00  | 2.72  | 1.85  | 2.52  | TGACCCCA | 14      | 2        | 2        | 2       |
| 2       | HSF1     | 1.00  | 1.35  | 9.20  | 2.07  | AGAAC  | 7.8     | 2        | 2        | 2       |

1Microarray data shown as fold change in expression from day 21 to day 56.
2Nucleotide abbreviations: N = G, A or T; K = G or T; Y = T or C; M = A or C; R = A or G.
3The Log-likelihood scores is a statistical measure representing the probability that a TF binding site exists in the region analyzed; we used a cutoff > 7.0. The higher the score the more likely the predicted sequence binds the target TF indicated.
4Number of binding sites identified in the different regions in the β-locus. For example there are 15, 21 and 10 predicted GATA1 binding sites in the LCR, γ-globin and β-globin regions respectively.
5Microarray data shown as fold change in expression from day 21 to day 56; Nucleotide abbreviations: N = G, A or T; K = G or T; Y = T or C; M = A or C; R = A or G; The Log-likelihood scores is a statistical measure representing the probability that a TF binding site exists in the region analyzed; we used a cutoff > 7.0. The higher the score the more likely the predicted sequence binds the target TF indicated.
6Number of binding sites identified in the different regions in the β-locus. For example there are 15, 21 and 10 predicted GATA1 binding sites in the LCR, γ-globin and β-globin regions respectively. doi:10.1371/journal.pone.0107133.t003
erythropoiesis derived from fetal versus adult stem cells supported by different TFN hubs however the same factors KLF1 and GATA1 serve at TFN hubs after the switch.

In vivo occupancy of TFs in the β-locus supported by ENCODE data

For the TFs identified by GSEA and predicted to bind the β-locus by TESS and TFSEARCH analysis of fetal erythroblasts, we search for evidence of in vivo binding using data generated with K562 cells in the ENCODE database. Shown in Figure 6A is RNA-seq data demonstrating high transcriptional activity in the LCR and globin genes except HBB which is not expressed in K562 cells. ChIP-seq data related to histone modification, and occupancy of genomic regions by TFs was analyzed. The methylation status of histone H3 shows enhancer-associated marks (H3K4me1) at the LCR and 5’ of HBG2. Furthermore, acetylated histone H3 (H3K9ac) is present in conjunction with H3K4me1 and H3K4me2/3, whereas H3K27me3 (inactive chromatin) is detected at low levels supporting an active chromatin confirmation in the β-locus.

We next searched the ENCODE database for TFs predicted to bind in the β-locus in our analysis (Table 3). We observed ATF3 occupancy in the LCR and upstream of HBG2 which co-localized with the enhancer mark H3K4me1. Interestingly, MXI1 binding was detected in the LCR and HBG genes suggesting a role of MXI1 in regulating γ-globin expression; this DNA binding protein may be a novel regulator not previously identified. The ENCODE data also revealed a diffuse pattern of GATA1 binding throughout the β-locus with concentrated GATA2 binding in the LCR. NFE2 is another globin gene regulator [40] that showed high occupancy at the LCR and HBG genes. p300 which is associated with enhancer activity [41] showed high occupancy at the LCR and HBG genes co-localized with the H3K4me1/H3K9Ac active marks in the LCR. The ENCODE findings were recently expanded by Xu et al [42] demonstrating a major role of histone modifications in developmentally regulated globin gene expression. In erythroblasts derived from second trimester fetal liver cells,
Figure 6. Data from the ENCODE project supports in vivo interaction of TFs. A) Shown are RNA-seq and ChIP-seq data for the β-locus (5,237,658 to 5,318,750) generated by the ENCODE consortium using K562 cells. Genes are indicated with arrows showing the direction of transcription. The numbers on the right side represents the maximum z-scores which correlate with signal strength. At the bottom of the panel, “K562 Inpt” refers to input chromatin incubated with negative control antibody. B) Shown are ChIP-seq and RNA-seq data for the HBG genes (5,264,860 to 5,277,966). The red box indicates the position for the cAMP responsive element at position -1222 relative to the HBG2 gene transcription start site.

doi:10.1371/journal.pone.0107133.g006
The highly expressed γ-globin gene was associated with activating histone marks H3K4me2/me3, H3K9ac and H3K27ac. By contrast, these marks are enriched around the adult δ- and β-globin genes in adult proerythroblast. These data support the combined role of lineage-specific regulators and co-regulator and stage-specific enhancers in developmentally regulated globin gene expression. Our data identified other potential co-regulators that function during erythropoiesis.

To gain a better perspective of the TFs implicated in HbF regulation, we studied factors at the genomic region covering the two HBG genes in detail (Figure 6B). Of note is the cAMP response element located at −2122 relative to the transcriptional start site of HBG2. This element is a positive regulatory sequence where transcription activity and H3K4me1 mark co-localize with CREB1 and p300 binding. Interestingly, ATF3 and MXI1 bind near the −2122 Gγ-globin cAMP response element, supporting a function in globin gene regulation. Moreover, the presence of the H3K4me2/3 and H3K9Ac marks demonstrates open chromatin across the HBG genes that may delineate an active chromatin domain for γ-globin expression during fetal development. Xu et al [42] observed TF occupancy across the β-locus of proerythroblast derived from fetal liver and adult stem cells. They concluded that a set of developmental stage-specific enhancers that are marked by histone marks are functionally active in a stage-specific manner. Whether similar histone marks and/or novel TFs such as ATF3 and MXI1 play a role in...

Figure 7. shRNA treatment of lead TFs augments γ-globin expression. KU812 cells were treated with shRNA lentiviral particles and selected with puromycin for 5 days followed by RT-qPCR and western blot analysis (see Materials and Methods). A) Shown is the fold change in γ-globin mRNA after treatment with the shRNA viral particles. γ-Globin expression was normalized by the percent of green fluorescent protein (GFP) positive cells representing transduction efficiency. B) RT-qPCR analysis was performed to confirm target gene silencing after shRNA treatment. ***p<0.0001 (C) Western blot analysis was performed to confirm target gene silencing. D) RT-qPCR analysis of gene expression in shKLF1-treated KU812 cells to determine potential downstream gene targets. E) Erythroid progenitors generated from UCB-SC were transduced with shRNA lentiviral particles and selected with puromycin for 5 days followed by RT-qPCR and FACS analysis. Shown is the level of γ/γ+β-globin ratio after shRNA treatments. F) Target gene silencing was quantified after shRNA transductions.

doi:10.1371/journal.pone.0107133.g007
hemoglobin switching during UCB-SC derived erythropoiesis requires further investigation.

**shRNA gene silencing identify novel repressors of HBG gene in primary erythroid cells**

To further support a functional role of TFs predicted to bind in the β-locus, we performed lentiviral-mediated shRNA gene silencing in KU812 cells [45] known to express the γ- and β-globin genes [46]. We focused our studies on TCF7L2 predicted to bind the HBG genes, MAFB predicted to bind HBB and GATA2 which binds across the β-locus, along with BCL11A and KLF1 known regulators of the γ/β-globin switch. shGATA2 transduction had no effect on γ-globin expression while knockdown of TCF7L2 and MAFB produced a 2.0-fold and 2.5-fold increase in γ-globin expression respectively (Figure 7A); as expected shBCL11A and shKLFL1 treatment reactivated γ-globin expression 2.5-fold and 9.2-fold respectively corroborating a repressor effect of these factors. Target gene silencing by shRNA treatment was confirmed by RT-qPCR and western blot with 50–80% reduction in target gene expression (Figure 7B, 7C). Since KLF1 has been demonstrated to be a potent repressor of γ-globin expression, we also performed qPCR using RNA isolated from shKLFL1 treated KU812 cells. KLF1 knockdown reduced BCL11A expression along with TCF7L2 and MAFB (Figure 7D) suggesting they might also be downstream targets. The regulation of BCL11A by KLF1 is consistent with previously published data [20,21]. By contrast, there was no significant change in GATA2 expression suggesting this factor is not regulated by KLF1.

Lastly, we conducted shRNA studies in primary erythroid cells generated from UCB-SC. On day 49 we treated erythroid progenitors with shTCF7L2, shMAFB, shGATA2, shBCL11A and scrambled controls. We chose this time point because γ-globin expression is low and there remain 40% polychromatophilic erythroblasts (Figure 1C) capable of responding to shRNA treatment. Puromycin was added on day 51 for 5 days and then cells were harvested for RT-qPCR and FACS analyses. We observed 35–70% target gene silencing (Figure 7E) which produced an increase in the γ/γ+β-globin ratio by 2.3-fold and 2-fold by shMAFB and shBCL11A treatment respectively (Figure 7F). The level of β-globin gene expression was not altered significantly by shRNA treatment (data not shown). MAFB is a leucine zipper TF predicted to bind the HBB region which plays a pivotal role in regulating lineage-specific hematopoiesis by repressing transcription of erythroid specific genes in myeloid cells [47] by interaction with the binding partner c-Ets1. Interestingly, the shRNA data suggest MAFB is a novel repressor of γ-globin however its molecular mechanism remains to be defined.

The findings suggest our bioinformatics analysis identified lead TFs not previously implicated in globin gene regulation however additional experimental data are required to confirm their *in vivo* functional role. In recent years, stem cells isolated from UCB have been investigated because of their high proliferation capacity and lack of tumorigenicity. The goal of our study was to delineate the transcriptome and unique TFNs involved in fetal erythropoiesis. We observed a higher proliferative capacity of UCB-CD34+ stem cells and normal erythroid maturation. In fetal erythroid progenitors the γ/β-globin switch occurred after day 42 demonstrating prolonged γ-globin gene expression compared to adult erythroid progenitors grown in the same culture conditions. Microarray analysis followed by GSEA and Cytoscape analysis defined major TFNs around KLF4 and GATA2 before γ-globin silencing and KLF1 and GATA1 after β-globin activation. shRNA-mediated gene silencing in erythroid progenitors derived from UCB-SC implicated MAFB as novel repressors of γ-globin expression consistent with our model that Profile-2 TFs are negative regulators. We also identified other novel TFs such as HEBS, ATF3, MXD3 and CLX1 among others (Table 5) predicted to bind the γ-globin promoter that can be analyzed by shRNA studies in fetal erythroblasts to define a functional role in globin gene regulation.

Fetal hemoglobin is a potent inhibitor of sickle hemoglobin polymerization and compensate for the globin chain imbalance in β-thalassemia. Clinical evidence indicates a modest increase in HbF, is a major modifier of the clinical phenotype and mortality in sickle cell disease [48]. Although hydroxyurea induces HbF in adults [12] and children [13], pharmacologic agents that specifically target hemoglobin switching have not been developed. Thus our results and others support development-stage specific control of globin gene expression that has important implications for the development of gene-based therapies for sickle cell disease and β-thalassemia. Several criteria must be met to define molecular targets of HbF induction including direct γ-globin silencing during erythropoiesis with limited off target effects and normal progression of hematopoiesis. For example, c-Myb may be a prospective target but its role in maintenance and differentiation of hematopoietic stem cells [49] raise concerns whether a safe therapeutic window can be achieved. Similar concerns about the development of BCL11A and KLF1 as therapeutic target exist. Recent studies to define the molecular mechanism of γ-globin regulation by BCL11A suggest targeting an erythroid specific enhancer in the first intron make this factor a promising target [50]. However there remains a need to identify other TFs that directly target γ-globin promoter regulatory elements and are expressed in a stage-specific manner to expand the repertoire of DNA-binding proteins that mediate HbF induction. The study herein and others [51] work towards this goal.

**Supporting Information**

| Table S1 Microarray normalized raw data for day 21, 42, 49 and 56. | (XLSX) |
| Table S2 Profile 1 and Profile-2 principal component analysis data. | (XLSX) |
| Table S3 Micorarray and RT-qPCR confirmation. | (XLSX) |
| Table S4 TESS/TFSEARCH analysis for locus control region. | (XLSX) |
| Table S5 TESS/TFSEARCH analysis for HBG region. | (XLSX) |
| Table S6 TESS/TFSEARCH results for HBB globin gene. | (XLSX) |
| Table S7 Adult stem cell Profile-1 (Class A) and Profile-2 (Class B) transcription factors. | (XLSX) |
| File S1 Supplementary figures. | (PPT) |

**Acknowledgments**

We would like to thank Dr. Hongyan Xu in the Department of Biostatistics at the Georgia Regents University for review of the statistical analysis. We
acknowledge the assistance of the Genomics Shared Resource at the Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center. The inclusion of trade names or commercial products in this article was solely for the purpose of providing specific information and does not imply recommendation of their products.

References

1. Robert A, Cortin V, Garnier A, Pineault N (2012) Megakaryocyte and platelet production from human cord blood stem cells. Methods Mol Biol 788: 219–47.
2. Geras C, Rhodes KE, Van Handel B, Chabra A, Ursus M, et al (2005) Hematopoietic stem cell development in the placenta. Int J Dev Biol 54: 1089–98.
3. Kindinger-TenRH, Hegerfeldt Y, Meyerson HJ, Markovics S, Fu P, et al (2012) Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies. Bone Marrow Transplantation 47: 924–33.
4. Ruggeri A, Eapen M, Scaravacch F, Cairo MS, Bhatia M, et al (2011) Center for International Blood and Marrow Transplant Research. New York Blood Center. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant 17: 1375–82.
5. Bolosati-Meade J, Brodsky RA (2009) Blood and marrow transplantation for sickle cell disease: a multicentre, randomised, controlled trial (BABY HUG). Lancet 332: 1317–22.
6. Peterson KR, Stamatoyannopoulos G (1993) Role of gene order in developmental control of human-gamma- and beta-globin gene expression. Mol Cell Biol 13: 4836–43.
7. Pillez G, Tabach Y, Rotschild M, Garach-Joshua O, Cohen Y, et al (2009) Identification of gene networks associated with erythropoietic differentiation. Blood Cells Mol Dis 43: 74–80.
8. Liu P, Barh J, Woodhouse K, Taylor JG, Munson P, et al (2011) Transcriptome profiling and sequencing of differentiated human hematopoietic stem cell lines reveal lineage-specific expression and alternative splicing of genes. Physical Genomics 11: 1137–144.
9. Merryweather-Clarke AT, Atzberger A, Sonje S, Gray N, Clark K, et al (2011) Global gene expression analysis of human erythroid progenitors. Blood 117: e96–108.
10. Li B, Ding L, Li W, Story MD, Pace BS (2012) Characterization 413 of the transcriptome profiles related to globin gene switching during in vitro erythropoiesis. BMC Genomics 13: 153–171.
11. Stamatoyannopoulos G, Grosveld F (2001) Hemoglobin switching. In: Stamatoyannopoulos G, Majerus P, Perlmutter R M, and Varmus H, eds., Molecular Basis of Blood Diseases, 3rd ed., W. B. Saunders, Philadelphia pp. 742–4.
12. Charache S, Terrin ML, Moore KD, Dover GJ, Barton FB, et al (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Results of the BABY HUG investigators. JAMA 273: 1663–72.
13. Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, et al (2011) BABY HUG: a novel, erythroid cell-specific murine transcription activator antagonism at the human beta-globin locus control region. Pediatr Hematol Oncol. 28: 708–17.
14. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, et al (1994) Mortality of the 487 patients enrolled in the writing of the manuscript: BL LD LL CY BK MS BP.
15. Keefer JR, Schneidereith TA, Mays A, Purvis SH, Dover GJ, et al (2006) Role of Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet 42: 801–5.
16. Stamatoyannopoulos G, Raich N, Eben A, Josephson B, Nakamoto B, et al (1990) Analysis of human gamma-to-beta switching in transgenic mice. Ann N Y Acad Sci 612: 127–33.
17. Uda M, Galanello R, Sanna S, Lettre G, Sankaran VG, et al (2008) Global gene expression analysis of human erythroid progenitors. Blood Cells Mol Dis 35: 227–35.
18. Xu J, Peng C, Sankaran VG, Shao Z, Esrick EB, et al (2011) Correction of sickle cell disease: overcoming barriers to success. Curr Opin Oncol 21: 158–61.
19. Miller IJ, Bieker JJ (1993) A novel, erythroid cell-specific murine transcription activator antagonism at the human beta-globin locus control region. Pediatr Hematol Oncol. 28: 708–17.
20. Zhang P, Basu P, Redmond LC, Morris PE, Rupon JW, et al (2005) A functional screen for KLF factors that regulate the human gamma-globin gene through displacement of a HDAC3/NCOR repressor complex. Blood 108: 3179–86.
21. Knaus HS, Alam MM, Choudhary PK, Pace BS (2011) KLF1 regulates HBG gene expression in primary erythroid cells. Br J Haematol 154: 240–59.
22. Welch JJ, Watts JA, Vakoc CR, Yao Y, Wang H, et al (2004) Global regulation of erythroid gene expression by transcription factor GATA-1. Blood 104: 3136– 47.
23. Pallak RB, Faller DV, Maberra R, Lowery CH, Boosalis MS, et al (2006) Short-chain fatty acids induce gamma-globin gene expression by displacement of a HDAC3/NCOR repressor complex. Blood Cells Mol Dis 35: 227–35.
24. Landry JR, Kinston S, Knezevic K, de Bruijn MF, Wilson N, et al (2008) Regulation of erythroid gene expression by transcription factor GATA-1. Blood 111: 3005–14.
25. He Y, Lin W, Lao J (2011) Influences of genetic variation on fetal hemoglobin. Hematol Oncol. 29: 708–17.
26. Pizzolo S, Basu P, Redmond LC, Morris PE, Rupon JW, et al (2005) A functional screen for KLF factors that regulate the human gamma-globin gene through the CACCC promoter element. Blood Cells Mol Dis 35: 227–35.
27. Ramanathan M, Martin IC, Gardiner-Garden M, Thomson PC, Taylor RM, et al (2000) Transcriptional activation of fetal gamma-globin gene expression with enhanced maternal performance in QG60 micce. BMC Genomics 9: 197–209.
28. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, et al (1994) Mortality of the patients enrolled in the writing of the manuscript: BL LD LL CY BK MS BP.
29. Kim A, Song SH, Brand M, Dran A (2007) Nucleosome and transcription activator antagonism at human beta-globin locus control region DNaI hypersensitive sites. Nucleic Acids Res 35: 5031–8.
30. Xue J, Shao Z, Glass K, Bauer DE, Pinello L, Van Handel B, et al (2012) Combinatorial assembly of developmental stage-specific enhancers controls gene expression programs during human erythropoiesis. Dev Cell 23: 796–811.
31. Sangerman J, Lee MS, Yao X, Oteng E, Hsiao CH, et al (2006) Mechanism for induction of fetal hemoglobin by histone deacetylase inhibitors involves gamma-globin activation by CREB1 and ATX-2. Blood 108: 3590–9.
32. Ramakrishnan V, Pace BS (2011) Regulation of gamma-globin gene expression involves signaling through the p38 MAPK/CREB1 pathway. Blood Cells Mol Dis 47: 12–22.
33. Platt OS, Brambilla DJ, Rosse WF, Maberra R, Castro O, et al (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330: 1639–44.

Characterization of Umbilical Cord Blood Erythropoiesis

Author Contributions

Conceived and designed the experiments: BP MS BL LD. Performed the experiments: BL LD BK CY LL. Analyzed the data: BP LD CY BK LL. Contributed reagents/materials/analysis tools: BP MS BL. Contributed to the writing of the manuscript: BL LD CY BK MS BP.

PLOS ONE | www.plosone.org 14 September 2014 | Volume 9 | Issue 9 | e107133
49. Satoh Y, Matsumura I, Tanaka H, Ezoe S, Sugahara H, et al (2004) Roles for CMYC in self-renewal of hematopoietic stem cells. J Biol Chem 279: 24986–24993.

50. Bauer DE, Kamran SC, Lessard S, Xu J, Fujivara Y, et al (2013) An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science 342: 253–7.

51. An X, Schulz VP, Li J, Wu K, Liu J, et al (2014) Global transcriptome analyses of human and murine terminal erythroid differentiation. Blood 123: 3466–77.